Meningococcal Group A, C Bivalent Polysaccharide Conjugate Vaccine

[Dosage Form] 

Freeze-dried powder for Injection

[Indication] 

It is indicated for prevention against diseases caused by Meningococcal Group A, C, such as cerebrospinal meningitis and septicemia (general infection) for Infants and children at the age of 3 months to 5 years.

[Specification] 

20µg/0.5ml/vial, 0.5ml per single human dose. Each dose of vaccine contains 10µg of each polysaccharide of group A and group C conjugated with tetanus toxoid respectively. 

[Route of Administration] 

Intramuscular injection

[Shelf life]
24 months